As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

As­traZeneca end­ed a Phase 2 tri­al of an ex­per­i­men­tal opi­oid use dis­or­der treat­ment, the UK phar­ma con­firmed to End­points News.

The ter­mi­na­tion was due to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER